Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Exploring the Different COVID Tests

On this episode of HealthFirst Talks, host Grace Huang welcomes two medical expert guests to discuss the different COVID-19 tests, their efficacy, and what test to use in different scenarios. Those guests are Dr. Scott Cohen, Chief Medical Information Officer and Chief Performance Improvement Officer for Bassett Healthcare Network, and Dr. Fiona Collins, dentist and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from HealthFirst on MarketScale.

Share

On this episode of HealthFirst Talks, host Grace Huang welcomes two medical expert guests to discuss the different COVID-19 tests, their efficacy, and what test to use in different scenarios. Those guests are Dr. Scott Cohen, Chief Medical Information Officer and Chief Performance Improvement Officer for Bassett Healthcare Network, and Dr. Fiona Collins, dentist and international speaker and author.

Drs. Cohen and Collins explained the two types of COVID-19 tests: PCR tests and antigen tests. “There are two broad types of COVID-19 diagnostic tests. The antigen test takes the nasal fluid and looks for the presence of the antigen. If so, it’s positive. The PCR is looking for the presence of coronavirus RNA,” Dr. Cohen said.

Which is more accurate? Dr. Collins explained, “When looking at accuracy, diagnostic tests can be high sensitivity or high specificity. With high sensitivity, you have very few false negatives. With high specificity, very few false positives.”

The doctors agreed that false negatives were more concerning for COVID-19. With a false positive, the worst that could happen is isolation. A false negative could lead to spread.

When looking at the two tests, Dr. Collins shared, “PCR tests have high specificity and sensitivity. Antigen is only high specificity. It can have a false-negative rate of 15-20%.”

With this in mind, PCR testing is clearly the stronger test, but it may not always be the best choice. For post-exposure testing, Collins said, “PCR is more reliable, but it will take a few days to get back, so patients should quarantine until results.”

In the case of mass testing, the antigen test may be better because it acts as a monitoring system, and people are being tested regularly. “Antigen testing is fastest and least expensive. No lab is needed. Because you’re regular testing, you can overcome the sensitivity issue,” Dr. Cohen added.

Learn more about COVID testing and precautions to take by watching the conversation.

HealthFirst

Part of this channel

HealthFirst

Practice-ready solutions for dental and medical offices nationwide.

Visit the channel

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tempus AI's $1.7B Personalis deal leads a surge in health-tech M&A that is already reshaping vendor choices for health system operators

Tempus AI's $1.7B Personalis deal leads a surge in health-tech M&A that is already reshaping vendor choices for health system operators

Digital health mergers and acquisitions (M&A) along with venture capital (VC) activities are rapidly increasing. Tempus AI's $1.7 billion acquisition of Personalis is part of a larger trend that is influencing health system operators’ selection of vendors. With $7.4 billion in funding during the first half of 2026, the health-tech industry is undergoing significant transformation.

  • 01Tempus AI acquired Personalis for $1.7 billion.
  • 02Health-tech received $7.4 billion in funding in the first half of 2026.
  • 03M&A activities are influencing vendor choices for health system operators.

Jul 30, 2026

Digital health AI investment hits $7.4B in H1 2026 as CMS, hospitals, and startups all accelerate adoption

Digital health AI investment hits $7.4B in H1 2026 as CMS, hospitals, and startups all accelerate adoption

In the first half of 2026, digital health AI investments reached $7.4 billion as organizations like CMS, hospitals, and startups increased their adoption of AI. Significant moves include the establishment of a new CMS technology office and a $1.7 billion acquisition in cancer technology. These developments mark an enterprise-level commitment to advancing AI in healthcare.

  • 01Digital health AI investments reached $7.4 billion in H1 2026.
  • 02The CMS established a new technology office to advance healthcare AI.
  • 03A major acquisition in cancer technology totaled $1.7 billion.

Jul 30, 2026

Sensor networks and AI push structural health monitoring toward a $8.6 billion market by 2035

Sensor networks and AI push structural health monitoring toward a $8.6 billion market by 2035

The global structural health monitoring (SHM) market is projected to surpass $8.6 billion by 2035. This growth is fueled by the integration of AI analytics, wireless sensor technologies, and the necessity to address aging infrastructure. The expansion reflects a widespread adoption of these technologies in various sectors.

  • 01The SHM market is expected to exceed $8.6 billion by 2035.
  • 02Advancements in AI-powered analytics and wireless sensors are key drivers of market growth.
  • 03Aging infrastructure is creating a demand for enhanced structural health monitoring solutions.

Jul 24, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512